Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV broadly neutralizing antibody
- Development stage
- Unknown
- Lead developer
- Eliteimmune
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
RSV broadly neutralizing antibody (including the lead candidate R66) is a fully human monoclonal antibody being developed by Eliteimmune for the prophylaxis of respiratory syncytial virus (RSV) infection. Discovered using Eliteimmune's proprietary CellProbe and CellSeq platforms, the antibody was isolated from an elite human donor and optimized to exhibit potent and broad neutralizing activity against diverse RSV clinical isolates. Eliteimmune is also developing next-generation bispecific and multispecific formats of the antibody designed to target distinct viral epitopes, such as the RSV fusion (F) protein, to prevent viral entry and provide robust protection. The candidate is currently in Phase I clinical development.
- Other names
- Next-gen RSV bispecific/multispecific antibodyNext-generation RSV bispecific/multispecific antibody
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV broadly neutralizing antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV broadly neutralizing antibody.